Serum proteomic profiling of obese patients: Correlation with liver pathology and evolution after bariatric surgery

Gut

Volumn 58, Issue 6, 2009, Pages 825-832

  Trak Smayra, V ^a,b   Dargere, D ^a   Noun, R ^c   Albuquerque, M ^a   Yaghi, C ^c   Gannage Yared M H ^c   Bedossa, P ^a,d   Paradis, V ^a,d  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

^d BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A; HEMOGLOBIN BETA CHAIN;

ADULT; AGED; ARTICLE; BARIATRIC SURGERY; CONTROLLED STUDY; DISEASE MARKER; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; AREA UNDER CURVE; BARIATRIC SURGERY; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; FIBROSIS; HEMOGLOBIN SUBUNITS; HEPATITIS; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; OBESITY, MORBID; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; PROTEIN ARRAY ANALYSIS; YOUNG ADULT;

EID: 66649083733     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2007.140087     Document Type: Article

References (34)

1. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:521-533 (Pubitemid 39141140)
2. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatoheptitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80. (Pubitemid 20075105)
3. Harrison SA, Torgeson S, Hayashi P. Natural history of NASH: a clinical histopathologic study. Am J Gastroenterol 2003;98:2042-2047
4. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-606 (Pubitemid 44307393)
5. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923 (Pubitemid 36397405)
6. Ruhl C, Everhart J. Epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis 2004;8:501-519
7. Fromenty B, Robin MA, Igodjil A, et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004;30:121-138 (Pubitemid 38715168)
8. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-744 (Pubitemid 32927998)
9. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138 (Pubitemid 40038911)
10. Van Der Poorten D, Kwok A, Lam T, et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J 2006;36:689-691 (Pubitemid 44563429)
11. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362
12. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123 (Pubitemid 30346988)
13. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100. (Pubitemid 32591518)
14. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36:142-149 (Pubitemid 34700771)
15. Wang H, Kachman MT, Schwartz DR, et al. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Proteomics 2004;4:2476-2495 (Pubitemid 39025348)
16. Cazares LH, Adam BL, Ward MD, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002;8:2541-2552
17. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-1502 (Pubitemid 32281313)
18. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2004;41:40-47
19. Zhang DH, Tai LK, Wong LL, et al. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 2005;5:1797-1805 (Pubitemid 40686225)
20. Chapman K. The ProteinChip biomarker system from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 2002;30:82-87
21. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321 (Pubitemid 40770284)
22. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence; 20-25 August 1995, Montreal. Morgan Kaufmann Publishers (www.mkp.com), 1995. Vol.2, pp. 1137-1145
23. Simon R, Radmacher MD, Dobbin K, et al. Pitfalls in the analysis of DNA microarray data: Class prediction methods. J Natl Cancer Inst 2003;95:14-18 (Pubitemid 36124291)
24. Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis 2004;8:535-547 (Pubitemid 39141141)
25. Abrams GA, Kunde SS, Lazenby AJ, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 2004;40:475-483 (Pubitemid 39062866)
26. Maddalena AS, Papassotiropoulos A, Gonzales-Agosti C, et al. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener Dis 2004;1:231-235 (Pubitemid 39551802)
27. Stanley BA, Gundry RL, Cotter RJ, et al. Heart disease, clinical proteomics and mass spectrometry. Dis Markers 2004;20:167-178 (Pubitemid 39314347)
28. Agranoff D, Stich A, Abel P, Krishna S. Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends Parasitol 2005;21:154-157 (Pubitemid 40381250)
29. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-674 (Pubitemid 41233660)
30. Cazzola J Rondanelli M, Russo-Volpe S, et al. Decreased membrane fluidity and altered susceptibility to peroxidation and lipid composition in overweight and obese female erythrocytes. J Lipid Res 2004;45:1846-1851 (Pubitemid 40990876)
31. Otogawa K, Kinoshita K, Fujii H, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007;170:967-980 (Pubitemid 47339365)
32. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931-939 (Pubitemid 34267276)
33. Reeder BJ, Sharpe MA, Kay AD, et al. Toxicity of myoglobin and haemoglobin: oxidative stress in patients with rhabdomyolysis and subarachnoid haemorrhage. Biochem Soc Trans 2002;30:745-748 (Pubitemid 35001646)
34. Reeder BJ, Wilson MT. Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease states. Curr Med Chem 2005;12:2741-2751 (Pubitemid 41601571)